Replies to post #2378 on BioLineRx Ltd (BLRX)

[midastouch017]

BioLineRx shares rise 8% after Motixafortide multiple myeloma pharmacoeconomic study results

Oct. 13, 2021 9:12 AM ETBioLineRx Ltd. (BLRX)

By: Aakash Babu, SA News Editor

BioLineRx (NASDAQ:BLRX) shares rise more than 8% premarket after posting positive results from a pharmacoeconomic study evaluating the cost-effectiveness of using Motixafortide as a primary stem cell mobilization (SCM) agent in certain patients with multiple myeloma.

The study concluded that the addition of Motixafortide to G-CSF (the current standard of care) is associated with a "statistically significant" decrease in health resource utilization (HRU) during the Autologous stem cell transplantation (ASCT) process, compared to G-CSF alone.

ASCT is part of the standard treatment paradigm for a number of blood cancers, including multiple myeloma, non-Hodgkin's lymphoma and other lymphomas.

The study findings, combined with model estimates, suggest that the use of Motixafortide, on top of G-CSF, as the standard of care in mobilization for ASCT, could be a cost-effective option in the US, based on accepted willingness-to-pay (WTP) values for healthcare payers.